VEGFA and neoplasm: In 2020, an immune checkpoint inhibitor (ICI) combined with an antivascular endothelial growth factor (anti-VEGF) monoclonal antibody (atezolizumab and bevacizumab) increased the tumor response rate to approximately 30% and overall survival (OS) to approximately 20 months [2].